Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 10, 2009, Pages 1421-1428

  Hara, Takeshi ^a   Tsurumi, Hisashi ^a   Goto, Naoe ^a   Kanemura, Nobuhiro ^a   Yoshikawa, Takeshi ^b   Kasahara, Senji ^a   Yamada, Toshiki ^a   Sawada, Michio ^c   Goto, Hideko ^d   Fukuno, Kenji ^c   Kitagawa, Jun Ichi ^a   Yasuda, Ichiro ^a   Katsumura, Naoki ^a   Takemura, Masao ^a   Takahashi, Takeshi ^b   Takami, Tsuyoshi ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Gifu Municipal Hospital   (Japan)

^c Gifu Red Cross Hospital   (Japan)

^d Kisogawa Municipal Hospital   (Japan)

Author keywords

Diffuse large B cell lymphoma (DLBCL); Prognostic analysis; Revised International Prognostic Index; Soluble Fas (sFas)

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FLUORODEOXYGLUCOSE; GALLIUM; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PIRARUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LARGE CELL CARCINOMA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 69049104100     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0586-4     Document Type: Article

References (28)

1. AA Alizadeh MB Eisen RE Davis C Ma IS Lossos A Rosenwald JC Boldrick H Sabet T Tran X Yu JI Powell L Yang GE Marti T Moore J Hudson Jr L Lu DB Lewis R Tibshirani G Sherlock WC Chan TC Greiner DD Weisenburger JO Armitage R Warnke R Levy W Wilson MR Grever JC Byrd D Botstein PO Brown LM Staudt 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503 511 10.1038/35000501
2. J Cheng T Zhou C Liu JP Shapiro MJ Brauer MC Kiefer PJ Barr JD Mountz 1994 Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule Science 263 1759 1762 10.1126/science.7510905
3. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors TA Lister J Vose A Grillo-López A Hagenbeek F Cabanillas D Klippensten W Hiddemann R Castellino NL Harris JO Armitage W Carter R Hoppe GP Canellos 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244 1253
4. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah P Morel E Van Den Neste G Salles P Gaulard F Reyes P Lederlin C Gisselbrecht 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 10.1056/NEJMoa011795
5. RI Fisher P Shah 2003 Current trends in large cell lymphoma Leukemia 17 1948 1960 10.1038/sj.leu.2403096
6. TS Griffith T Brunner SM Fletcher DR Green TA Ferguson 1995 Fas Ligand-induced apoptosis as a mechanism of immune privilege Science 270 1189 1192 10.1126/science.270.5239.1189
7. C Haioun E Lepage C Gisselbrecht Y Bastion B Coiffier P Brice A Bosly B Dupriez C Nouvel H Tilly P Lederlin P Biron J Brière P Gaulard F Reyes 1997 Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 15 1131 1137
8. T Hara H Tsurumi M Takemura H Goto T Yamada M Sawada T Takahashi H Moriwaki 2000 Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma Am J Hematol 64 257 261 10.1002/1096-8652(200008)64:4<257::AID-AJH4>3.0.CO;2-2
9. A Ichikawa T Kinoshita T Watanabe H Kato H Nagai K Tsushita H Saito T Hotta 1997 Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma N Engl J Med 337 529 534 10.1056/NEJM199708213370804
10. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors, pathology and genetics tumors of haematopoietic and lymphoid tissues. IARC, Lyon, pp 109-236
11. M Martelli F Gherlinzoni A De Renzo PL Zinzani A De Vivo M Cantonetti B Falini S Storti G Meloni M Rizzo AL Molinari F Lauria L Moretti VM Lauta P Mazza L Guardigni E Pescarmona SA Pileri F Mandelli S Tura 2003 Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial J Clin Oncol 21 1255 1262 10.1200/JCO.2003.01.117
12. AA Miller E Salewski 1994 Prospects for pirarubicin Med Pediatr Oncol 22 261 268 10.1002/mpo.2950220410
13. N Milpied E Deconinck F Gaillard V Delwail C Foussard C Berthou R Gressin V Lucas P Colombat JL Harousseau Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang 2004 Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support N Engl J Med 350 1287 1295 10.1056/NEJMoa031770
14. S Nagata 1997 Apoptosis by death factor Cell 88 355 365 10.1016/S0092-8674(00)81874-7
15. C Nicolaides S Dimou N Pavlidisa 1998 Prognostic factors in aggressive non-Hodgkin's lymphomas Oncologist 3 189 197
16. N Niitsu J Okabe-Kado T Kasukabe Y Yamamoto-Yamaguchi M Umeda Y Honma 1999 Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma Blood 94 3541 3550
17. N Niitsu J Okabe-Kado M Okamoto T Takagi T Yoshida S Aoki M Hirano Y Honma 2001 Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma Blood 97 1202 1210 10.1182/blood.V97.5.1202
18. N Niitsu Y Honma K Iijima T Takagi M Higashihara U Sawada J Okabe-Kado 2003 Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma Leukemia 17 196 202 10.1038/sj.leu.2402699
19. G Papoff I Cascino A Eramo G Starace DH Lynch G Ruberti 1996 An N-terminal domain shared by Fas/Apo-1(CD95) soluble variants prevents cell death in vitro J Immunol 156 4622 4630
20. M Sawada H Tsurumi T Yamada T Hara K Fukuno H Goto M Shimizu S Kasahara T Yoshikawa N Kanemura M Oyama T Takami H Moriwaki 2002 A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy Eur J Haematol 68 354 361 10.1034/j.1600-0609.2002.01654.x
21. LH Sehn B Berry M Chhanabhai C Fitzgerald K Gill P Hoskins R Klasa KJ Savage T Shenkier J Sutherland RD Gascoyne JM Connors 2007 The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 1857 1861 10.1182/blood-2006-08-038257
22. MA Shipp MD Abeloff KH Antman G Carroll A Hagenbeek M Loeffler E Montserrat JA Radford G Salles N Schmitz M Symann JO Armitage T Philip B Coiffier 1999 International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury J Clin Oncol 17 423 429
23. T Suda T Takahashi P Golstein S Nagata 1993 Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family Cell 75 1169 1178 10.1016/0092-8674(93)90326-L
24. T Takagi M Oguro 1987 (2″-R)-4′-o- tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies Cancer Chemother Pharmacol 20 151 154 10.1007/BF00253970
25. The International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993 A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 987 994 10.1056/NEJM199309303291402
26. The Non-Hodgkin's Lymphoma Pathologic Classification Project 1982 National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage Cancer 49 2112 2135 10.1002/1097-0142(19820515)49:10<2112::AID- CNCR2820491024>3.0.CO;2-2
27. H Tsurumi T Yamada M Sawada S Kasahara N Kanemura Y Kojima K Fukuno T Hara M Saio T Takahashi M Oyama K Ozawa T Takami H Moriwaki 2004 Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study J Cancer Res Clin Oncol 130 107 113 10.1007/s00432-003-0508-9
28. H Tsurumi T Hara N Goto N Kanemura S Kasahara M Sawada I Yasuda T Yamada M Shimizu T Takami H Moriwaki 2007 A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma Hematol Oncol 25 107 114 10.1002/hon.815